Skip to content

May 15, 2026

ChatGPT Image May 7, 2026, 07_11_28 PM

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Clinical Data
ECO 2026: tirzepatide shows potential for T1D treatment

Clinical Data

ECO 2026: tirzepatide shows potential for T1D treatment

Pharmaceutical Technology

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

Metabolic & GLP-1

Read full story

pharminent May 15, 2026

Pharmaceutical Technology

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

Metabolic & GLP-1

Read full story

Post navigation

Previous: Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

Next: Biopharma industry endorses Pazdur for FDA commissioner role

Related Stories

Clinical Data

Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate

pharminent May 15, 2026

Clinical Data

Regenxbio’s Duchenne gene therapy clears phase 3 hurdle

pharminent May 14, 2026

Clinical Data

BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

pharminent May 12, 2026

You May Have Missed

M&A / Deals

Arna Pharma and Slate Run complete JV for new US company

pharminent May 15, 2026

Commercial

Lilly UK recruits ex-England cricketer as obesity champion

pharminent May 15, 2026

Regulatory

Biopharma industry endorses Pazdur for FDA commissioner role

pharminent May 15, 2026

Clinical Data

ECO 2026: tirzepatide shows potential for T1D treatment

pharminent May 15, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.